Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 22, Issue 1, 2004, Pages 32-35

  Borrega, Pablo ^a   Velasco, Amalia ^b   Bolaños, Matilde ^a   Del Mar Pérez, María ^b   Mel, José Ramón ^c   Reina, Juan José ^d   Rodríguez Jaraiz, María Angeles ^a   Chaves, Manuel ^a   González Barón, Manuel ^e  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL XERAL CALDE   (Spain)

^d HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Estramustine; Phase II; Prostate cancer; Vinorelbine

Indexed keywords

ESTRAMUSTINE; NAVELBINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HEART MUSCLE ISCHEMIA; HUMAN; LIVER ISCHEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; VINBLASTINE;

EID: 2142764420     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(03)00102-9     Document Type: Article

References (16)

1. Oh W.K., Kantoff P.W. Management of hormone refractory prostate cancer current standards and future prospects. J Urol. 60:1998;1220-1229
2. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 17:1999;3461-3467
3. Gregory R.K., Smith I.E. Vinorelbine - a clinical review. Br J Cancer. 82:1997;1907-1913
4. Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol. 15:1997;13-19
5. Kaplan E.L., Meier P. Non-parametric estimations from incomplete observations. J Am Stat Assoc. 53:1958;457-481
6. Plowman P.N., Perry L.A., Chard T. Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer. Br J Urol. 59:1987;255-257
7. Pienta K.J., Reploge T., Lehr J. Inhibition of prostate cancer growth by tamoxifen and vinblastine. Prostate. 26:1995;270-274
8. Polin L., Valeriote F., White K., et al. Treatment of human prostate tumors PC-3 and TSU-PR with standard and investigational agents in SCID mice. Invest New Drugs. 15:1997;99-108
9. Dexeus F.H., Logothetis C., Samuels M., et al. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep. 69:1985;885-886
10. Hudes G., Einhorn L., Ross E., et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer a Hoosier Oncology Group and Fox Chase Network Phase III trial. J Clin Oncol. 17:1999;3160-3166
11. Fields-Jones S., Koletsky A., Wilding G., et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer a phase II trial. Ann Oncol. 10:1999;1307-1310
12. Hudes G.R., Nathan F., Khater C., et al. Phase II trial of 96-paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 15:1997;3156-3163
13. Ellerhorst J.S., Tu S.-M., Amato R.J., et al. Phase II trial alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 3:1997;2371-2376
14. Perry C.M., McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 7:1995;49-74
15. Smith M.R., Kaufman D., Oh W., et al. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer. Cancer. 89:2000;1824-1828
16. Kish J.A., Bukkapatnam R., Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control. 8:2001;487-495